181 reports of this reaction
2.1% of all DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN reports
#10 most reported adverse reaction
HEADACHE is the #10 most commonly reported adverse reaction for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, manufactured by RB Health (US) LLC. There are 181 FDA adverse event reports linking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN to HEADACHE. This represents approximately 2.1% of all 8,751 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 181 FDA reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.1% of all adverse event reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, making it a notable side effect.
If you experience headache while taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.